Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2015—Mindray received 510(k) clearance to market and sell the Mindray BC-3600 Auto Hematology Analyzer, which aims to meet the testing needs of small and mid-volume hematology laboratories. The BC-3600 Hematology Analyzer features closed-tube sampling via a single push button.
November 2015—Clarient Diagnostics will offer the FDA-approved PD-L1 companion diagnostic, which will help identify patients most likely to benefit from Merck’s lung cancer drug Keytruda.
November 2015—Illumina has launched TruSight Tumor 15, a next-generation sequencing panel designed to identify sequence variants in 15 genes commonly associated with marketed therapeutics. The sequencing panel is optimized for damaged and degraded formalin-fixed, paraffin-embedded tumor samples, enabling low frequency somatic variant detection from limited nucleic acid inputs.
November 2015—Maine Standards released its Validate SP2 calibration verification/linearity test kit, which evaluates albumin, C-reactive protein, haptoglobin, and prealbumin in a human-serum–based matrix.
November 2015—Streck has acquired Fertility Solutions’ sperm count and post-vasectomy quality control products. The sperm count controls for fertility diagnosis have been renamed Sperm-Chex and Sperm-Chex Post VC.
November 2015—Biocare Medical announced the availability of CK HMW + p63 + AMACR (RM) as an in vitro diagnostic double stain for multiplex immunohistochemistry. This patented antibody cocktail may be useful in the evaluation of normal prostate glands, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma.
November 2015—Thermo Fisher Scientific received the in vitro diagnostics device CE mark for its Thermo Scientific Prelude MD HPLC, Endura MD mass spectrometer, and ClinQuan MD software.
November 2015—Irvine Scientific received CE mark approval for its Human Serum Albumin Solution (100 mg/mL) in normal saline. HSA is used in assisted reproductive procedures as a protein supplement for gamete and embryo manipulation.
Roche has signed a definitive agreement to acquire Kapa Biosystems, a privately held company that employs proprietary technologies to optimize enzymes for next-generation sequencing as well as polymerase chain reaction and real-time PCR applications.
Biocartis launched its CE-IVD Idylla KRAS Mutation Test, a sample-to-result test for the fast, accurate, and reproducible detection of 21 relevant mutations in the KRAS oncogene. The fully automated test, for routine use, detects all clinically relevant driver mutations of the KRAS oncogene in tissue of colorectal cancers at a sensitivity of five percent.
